Publication: Estudio del valor pronóstico de las células tumorales circulantes y de la utilidad de su caracterización molecular en pacientes con cáncer colorrectal y cáncer de cabeza y cuello en estadio avanzado
Loading...
Official URL
Full text at PDC
Publication Date
2021-07-16
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citations
Exportar
Abstract
El adenocarcinoma colorrectal (CCR) y el cáncer de cabeza y cuello (CCC) son dos cánceres prevalentes y con tasas de supervivencia notablemente mejorables. Las células tumorales circulantes (CTC) constituyen una modalidad de biopsia líquida cuya utilidad como reservorio de información molecular ha sido insuficientemente estudiada. CellSearch®, un método de inmunoafinidad que emplea anticuerpos anti-EpCAM, es el sistema de detección de CTC más utilizado hasta la fecha y el único aprobado por la FDA para su uso asistencial, pero sólo permite la enumeración y no la recuperación de CTC para su caracterización molecular. IsoFlux™ es un sistema de enriquecimiento de CTC por inmunoafinidad que emplea también anticuerpos anti-EpCAM, y que además de la enumeración de CTC permite su recuperación para realizar análisis moleculares. IsoFlux™ solo ha sido evaluado previamente en una pequeña y heterogénea serie de pacientes con CCR y nunca se ha testado en pacientes con CCC.
El objetivo principal de este estudio fue comparar la capacidad en la enumeración de CTC de CellSearch® e IsoFlux™ en pacientes con CCR metastásico (CCRm). Los objetivos secundarios fueron la evaluación de diferentes métodos de análisis mutacional en ADN de CTC recuperadas con IsoFlux™ en CCRm y la enumeración y recuperación de CTC por IsoFlux™ y su análisis mutacional en pacientes con CCC en fase recurrente/metastásica (R/M)...
Colorectal adenocarcinoma (CRC) and head and neck carcinoma(HNC) are prevalent cancers with poor survival rates. Circulating tumor cells (CTC) constitute a liquid biopsy modality that has been insufficiently studied as a reservoir of molecular information. CellSearch®, an immunoaffinity-based method that uses anti-EpCAM antibodies, is the most widely used CTC detection system to date and the only one approved by the FDA for healthcare use. However, CellSearch® only allows enumeration and not the recovery of CTC for molecular characterization. IsoFlux™ is an immunoaffinity-based CTC enrichment method that also uses anti-EpCAM antibodies. In addition to enumeration, IsoFlux™ permits CTC recovery for molecular analysis, but has only been previously evaluated in a small and heterogeneous series of patients with CRC and has never been tested in patients with HNC. The primary endpoint of this study was to compare the ability to enumerate CTC with CellSearch® and IsoFlux™ in patients with metastatic CRC (mCRC). Secondary endpoints were the evaluation of different methods of mutational analysis in CTC recovered with IsoFlux™ in mCRC and the enumeration and recovery of CTC with IsoFlux™ and their mutational analysis in patients with recurrent/metastatic (R/M) HNC...
Colorectal adenocarcinoma (CRC) and head and neck carcinoma(HNC) are prevalent cancers with poor survival rates. Circulating tumor cells (CTC) constitute a liquid biopsy modality that has been insufficiently studied as a reservoir of molecular information. CellSearch®, an immunoaffinity-based method that uses anti-EpCAM antibodies, is the most widely used CTC detection system to date and the only one approved by the FDA for healthcare use. However, CellSearch® only allows enumeration and not the recovery of CTC for molecular characterization. IsoFlux™ is an immunoaffinity-based CTC enrichment method that also uses anti-EpCAM antibodies. In addition to enumeration, IsoFlux™ permits CTC recovery for molecular analysis, but has only been previously evaluated in a small and heterogeneous series of patients with CRC and has never been tested in patients with HNC. The primary endpoint of this study was to compare the ability to enumerate CTC with CellSearch® and IsoFlux™ in patients with metastatic CRC (mCRC). Secondary endpoints were the evaluation of different methods of mutational analysis in CTC recovered with IsoFlux™ in mCRC and the enumeration and recovery of CTC with IsoFlux™ and their mutational analysis in patients with recurrent/metastatic (R/M) HNC...
Description
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Medicina, Departamento de Medicina, leída el 12/02/2021